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Vaccine manufacturing supply chains are characterized by long lead times
which may exceed 300 days. Such long lead times make it challenging to guar-
antee on-time deliveries. The long lead times are determined by the high-volume
manufacturing processes (formulation, ﬁlling and packaging), but they are espe-
cially the result of the stringent quality control and quality assurance procedures.
For vaccine manufacturing, the touch time is only 5 to 10% of the total lead time
which indicates that it is worthwhile to study the impact of capacity on the lead
times of the quality processes into more detail. For such supply chain stages,
these long lead times are partly due to limited capacity in terms of laboratory
equipment as well as skilled people.
The Quality Control (QC) and Quality Assurance (QA) department guaran-
tees persistence of quality during these processes by various tests. To continue
the manufacturing processes (formulation, ﬁlling and packaging), some critical
tests (e.g. sterility tests) need to be performed immediately after the formula-
tion and ﬁlling stages to identify whether the vaccines are allowed to proceed to
the next stage. When the results of these critical tests are positive, the vaccines
are put in a restricted status and may proceed to the next manufacturing stage.
The other quality requirements, the QC and QA, are performed in parallel with
the subsequent manufacturing stages as the lead times of these quality stages
can be long. Each QC/QA stage (for formulation, ﬁlling and packaging) can be
decomposed into four independent processes:
1. Actual quality testing of the product
1
2. Investigation of deviations in the actual testing (e.g. due to the calibration
of laboratory instruments)
3. Document review of the production activities
4. Request for Process Change: post-approval regulatory process to change the
manufacturing process according to customers' requirements. Such changes
may include changes to the vaccine composition, quality control, equipment,
facilities or product labelling information after a vaccine has been approved
Queuing networks and the Guaranteed Service Approach (GSA) are two well
established modeling methodologies. However, as both models include nonlinear
eﬀects, Lemmens et al. (2016) mention that the direct impact of the capacity on
the GSA's resulting stock levels is particularly cumbersome to derive with a re-
sulting closed-form expression. To integrate both models, Lemmens et al. (2016)
demonstrate the following three steps to embed capacity into the Guaranteed
Service Approach with Variable lead times (GSA-VAR):
1. Calculate the average and variance of the lead time using batch queuing
networks
2. Characterize the entire lead time distribution
3. Extend the lead time information obtained in previous steps into the GSA-
VAR (Humair et al. (2013))
In this work, step 1 will be replaced with an approximate queuing method-
ology to calculate the average and variance of the lead time of two capacity-
dependent quality process nodes: the investigation of deviations for formulation
and ﬁlling. In this way, we study the impact of adding diﬀerent capacity levels
to these quality processes on the total lead time and diﬀerent types of stock.
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